Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16072732 | 0.91 | GNAI3 (0.51) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL13498645 | 0.88 | GNAI3 (0.56) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL19001329 | 0.88 | ALDH1A1 (0.48) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL16072731 | 0.85 | GNAI3 (0.59) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL6043709 | 0.84 | ALDH1A1 (0.48) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL13498641 | 0.84 | GNAI3 (0.51) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL6043717 | 0.84 | ALDH1A1 (0.48) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL16072734 | 0.82 | GNAI3 (0.68) | GNAI3GNAO1GNAI1ALDH1A1ITGB3 | |
| SCHEMBL16072733 | 0.82 | GNAI3 (0.68) | GNAI3GNAO1GNAI1ALDH1A1ITGB3 | |
| SCHEMBL10274497 | 0.82 | GNAI3 (0.58) | GNAI3GNAO1GNAI1ALDH1A1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | GNAI3 861/4885GNAO1 1452/4885GNAI1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.